小剂量654-2联合川芎嗪治疗糖尿病周围神经病变临床效果观察

Clinical research for treatment of diabetic peripheral neuropathy by combination therapy with small doses of anisodamine injection and ligustrazine injection

目的探讨小剂量654-2注射液联合川芎嗪注射液治疗糖尿病周围神经病变患者的效果及安全性。方法选取糖尿病周围神经病变患者60例,随机分为对照组及治疗组各30例。对照组口服甲钴胺及依帕司他治疗,治疗组在对照组基础上应用小剂量654-2注射液及川芎嗪注射液治疗,疗程均为2周。比较2组临床疗效,治疗前后检测超敏C反应蛋白(high sensitive C reaction protein,hsCRP)水平,多伦多临床评分系统(Toronto Clinical Scoring System,TCSS)评分,双侧正中神经、腓总神经、胫神经的运动传导速度(motor nerve conduction velocity,MNCV)和正中神经、腓肠神经的感觉传导速度(sensory nerve conduction velocity,SNCV)。结果治疗后,2组hsCRP含量均明显低于治疗前,治疗组hsCRP含量明显低于对照组(P<0.05)。2组正中神经MNCV、腓总神经MNCV、胫神经MNCV、正中神经SNCV、腓肠神经SNCV均明显高于治疗前,且治疗组腓总神经MNCV、胫神经MNCV、正中神经SNCV、腓肠神经SNCV均明显高于对照组(P<0.05)。治疗组临床疗效优于对照组,总有效率高于对照组(P<0.05)。2组TCSS评分均明显低于治疗前,治疗组TCSS评分低于对照组,差异有统计学意义(P<0.05)。治疗组TCSS评分疗效优于对照组,总有效率明显高于对照组(P<0.05)。结论小剂量654-2联合川芎嗪治疗糖尿病周围神经病变是相对安全的,而且经济有效,特别对于基层患者在减少药费及社保费用支出等方面有实际的意义。

Objective To investigate the efficacy and safety of low-dose anisodamine injection combined with tetramethylpyrazine injection in the treatment of patients with diabetic neuropathies.Methods Sixty patients with diabetic neuropathies were randomly divided into control group and treatment group,30 cases in each group.The control group was treated with Mecobalamin and Epalrestat.The treatment group was treated with low-dose anisodamine and Tetramethylpyrazine injection in addition to the medicine used in the control group.The treatment lasted 2 weeks.The following data were used to compare the clinical efficacy of the two groups before and after treatment:the level of high sensitive C reaction protein(hsCRP);the score of the Toronto Clinical Scoring System(TCSS);the motor nerve conduction velocity(MNCV)of bilateral median nerve,common peroneal nerve,tibial nerve and the sensory nerve conduction velocity(SNCV)of median nerve,sural nerve.Results After treatment,the hsCRP levels in both groups were significantly lower than those before treatment,and the hsCRP levels in the treatment group were significantly lower than those in the control group(P<0.05).In both groups,the MNCV data of median nerve,the common peroneal nerve,the radial nerve and median nerve and the sural nerve were significantly higher than those before treatment,and the MNCV date of common peroneal nerve,tibial nerve and the SNCV data of median nerve,sural nerve were higher than those of control group(P<0.05).The clinical efficacy of the treatment group was better than that of the control group,and the total effective rate was higher than that of the control group(P<0.05).The TCSS scores of the two groups were significantly lower than those before treatment.The TCSS scores of the treatment group were lower than the control group(P<0.05).The TCSS score of the treatment group was better than that of the control group,and the total effective rate was significantly higher than that of the control group(P<0.05).Conclusion The treatment of diabetic neuropathies with low-dose anisodamine combined with tetramethylpyrazine is relatively safe and cost-effective,especially for grassroots patients with primary disease who have practical clinical significance in reducing drug costs and social security expenses.